Status:
COMPLETED
Acute Kidney Injury in Cancer Patients Receiving Anti-Vascular Endothelial Growth Factor Monoclonal Antibody vs Immune Checkpoint Inhibitors
Lead Sponsor:
First Affiliated Hospital of Wenzhou Medical University
Conditions:
AKI Incidence of Cancer Patients Receiving AntiVEGF or ICIs
Eligibility:
All Genders
20+ years
Brief Summary
The goal of this a retrospective real-world study is to compare the AKI events in cancer patients receiving anti-vascular endothelial growth factor monoclonal antibody (AntiVEGF) vs immune checkpoint ...
Eligibility Criteria
Inclusion
- Age \>=20yr;
- Patients must have at least one "Evaluation and Management"visit with a diagnosis of cancer within 12 months before index date (In situ biopsy will not be required, since patients may receive a diagnosis from a biopsy of metastatic site);
- Indication to initiate AntiVEGF or ICIs
Exclusion
- Patients without valid data and less than 3 months followup;
- Patients without baseline Scr value within 12 mon before index date;
- Patients with combination therapy of Anti-VEGF and ICIs ;
- Patients with chronic renal failure
Key Trial Info
Start Date :
January 1 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
October 10 2023
Estimated Enrollment :
1581 Patients enrolled
Trial Details
Trial ID
NCT06119347
Start Date
January 1 2020
End Date
October 10 2023
Last Update
November 8 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The First Affiliated Hospital of Wenzhou Medical University
Wenzhou, Zhejiang, China, 325000